Longitudinal studies of hepatic fibrosis, including ongoing trials of simtuzumab in NASH and advanced liver fibrosis, will contribute to the understanding of the function of LOXL2 in fibrosis progression and portal hypertension. The gene discussed is LOXL2; the disease is metabolic dysfunction-associated steatohepatitis.